I have had two very exciting days, full of interesting discussions om pharmaceuticals and the environment, in three very different fora. Yesterday morning I had an internal meeting at the Pfizer office in Silverdal in Sollentuna, Sweden, where I met Pfizer colleagues working with our off-patent product portfolio. We had good discussions on green pharmaceuticals:
- What it is
- How to evaluate greenness and how to ”certify” it
- And what type of business opportunities there could be with a greener product portfolio
We of course entered in to really interesting discussions on green critiera and green economic incentives. For details on these matters please read my blog posts from e.g. Oct 3, Sept 28, and Sept 23. We also tried to put the ”greener product portfolio discussions” in a broader perspective of other types of ”added values” we can bring to society. For more details on these ideas read the blog post from e.g. Oct 4 and Aug 23. Please also read a detailed discussion on ”4 steps to a sustanable use of pharmaceuticals” in the blog post from Feb 8.
After the internal meeting, I met with the expert group on Pharmaceuticals and the Environment, supporting the All Party Committee on Environmental Objectives (in Swedish ”Miljömålsberedningen”). You can read about our work in my blog posts from e.g. Nov 14 and Sept 19. It is really a privilege to sit down and have very open and honest discussions with representatives from pretty much every single stakeholder in the sector. Not surprisingly we had good and long discussions on several of the ideas on actions/objectives that were originally presented by the Swedish MPA in the Dec 16, 2009 report on ”increased environmental requirements on pharmaceutical manufacturing” (find some of my comments to those ideas in my blog post from Dec 17, 2009):
- Inclusion of environmental requirements in GMP
- Inclusion of Environmental Risk Assessments into the market authorization process for pharmaceuticals
- Considerations of environmental aspects in the pricing and reimbursement system, i.e. green criteria and green economic incentives
And today, the discussions on these matters and others continued when LIF’s (LIF - the Swedish Research Based Pharmaceutical Industry Association) environmental committee met at the LIF Office in Stockholm. For me it was a special meeting, since I ”transferred” from chairman of the committee to ”administratively responsible” for the committee. The reason of course that I nowadays work part time at the LIF Office. And I like to take the opportunity here to say thanks for all support Matilda Holst have given me during the years in her role at the LIF Office when I have been working as the chairman, and to also welcome Gisela Holm from AstraZeneca as the new chairperson of the committee.
In addition to the already mentioned items up for discussion today at the committee meeting, we also had a good presentation made by Karl Lilja from IVL, the Swedish Environmental Research Institute, on the environmental classification of pharmaceutical substances scheme at Fass.se. IVL has been the reviewer of all company submissions of environmental classifications of pharmaceutical substances since the beginning of 2005, so they have built up a significant amount of knowledge, experience and data. Read more about the Swedish classification scheme at Fass.se and on LIF’s web site.
So many interesting discussions – it is really a privilege to be working with all these people in such an interesting field! I am really looking forward to 2012! Discussions will be more intense, and more interesting, than ever!